CorMedix Inc. (NYSE MKT: CRMD) is a commercial-stage biopharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases, according to the company’s website (see here: www.CorMedix.com). SNNLive spoke with Randy Milby, CEO of CorMedix Inc. at the Marcum MicroCap Conference 2016 in New York City, NY.
In this video interview, Mr. Milby and our host discuss the following topics:
- Overview of CorMedix, Inc.
- How the company’s biotechnology works
- What it replaces
- Size of the market
- Clinical development
- Where the science was developed
- Mr. Milby’s background
For more information about CorMedix Inc., please visit: www.CorMedix.com
The interview may contain forward-looking statements about CorMedix Inc. See CorMedix's periodic filings with the Securities and Exchange Commission for more complete information.
© 2017 Stock News Now
Supported by Superior Web Solutions